119 related articles for article (PubMed ID: 9496259)
1. Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed müllerian tumours.
Abeln EC; Smit VT; Wessels JW; de Leeuw WJ; Cornelisse CJ; Fleuren GJ
J Pathol; 1997 Dec; 183(4):424-31. PubMed ID: 9496259
[TBL] [Abstract][Full Text] [Related]
2. Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis.
Jin Z; Ogata S; Tamura G; Katayama Y; Fukase M; Yajima M; Motoyama T
Int J Gynecol Pathol; 2003 Oct; 22(4):368-73. PubMed ID: 14501818
[TBL] [Abstract][Full Text] [Related]
3. High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers.
Eiriksdottir G; Barkardottir RB; Agnarsson BA; Johannesdottir G; Olafsdottir K; Egilsson V; Ingvarsson S
Oncogene; 1998 Jan; 16(1):21-6. PubMed ID: 9467939
[TBL] [Abstract][Full Text] [Related]
4. Allelotype of papillary serous peritoneal carcinomas.
Cass I; Baldwin RL; Fasylova E; Fields AL; Klinger HP; Runowicz CD; Karlan BY
Gynecol Oncol; 2001 Jul; 82(1):69-76. PubMed ID: 11426964
[TBL] [Abstract][Full Text] [Related]
5. Histogenesis of sarcomatoid urothelial carcinoma of the urinary bladder: evidence for a common clonal origin with divergent differentiation.
Sung MT; Wang M; MacLennan GT; Eble JN; Tan PH; Lopez-Beltran A; Montironi R; Harris JJ; Kuhar M; Cheng L
J Pathol; 2007 Mar; 211(4):420-30. PubMed ID: 17236170
[TBL] [Abstract][Full Text] [Related]
6. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.
Wang C; Horiuchi A; Imai T; Ohira S; Itoh K; Nikaido T; Katsuyama Y; Konishi I
J Pathol; 2004 Feb; 202(2):215-23. PubMed ID: 14743504
[TBL] [Abstract][Full Text] [Related]
7. Clonal origin of lymph node metastases in bladder carcinoma.
Jones TD; Carr MD; Eble JN; Wang M; Lopez-Beltran A; Cheng L
Cancer; 2005 Nov; 104(9):1901-10. PubMed ID: 16196038
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer.
Manderson EN; Presneau N; Provencher D; Mes-Masson AM; Tonin PN
Mol Carcinog; 2002 Jun; 34(2):78-90. PubMed ID: 12112314
[TBL] [Abstract][Full Text] [Related]
9. Loss of heterozygosity at chromosome 9p21 is a frequent finding in enteropathy-type T-cell lymphoma.
Obermann EC; Diss TC; Hamoudi RA; Munson P; Wilkins BS; Camozzi ML; Isaacson PG; Du MQ; Dogan A
J Pathol; 2004 Feb; 202(2):252-62. PubMed ID: 14743509
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of P16 and P53 expression in uterine malignant mixed mullerian tumors.
Buza N; Tavassoli FA
Int J Gynecol Pathol; 2009 Nov; 28(6):514-21. PubMed ID: 19851197
[TBL] [Abstract][Full Text] [Related]
11. Molecular genetic evidence supporting the neoplastic nature of the Leydig cell component of ovarian Sertoli-Leydig cell tumors.
Emerson RE; Wang M; Roth LM; Zheng W; Abdul-Karim FW; Liu F; Ulbright TM; Eble JN; Cheng L
Int J Gynecol Pathol; 2007 Oct; 26(4):368-74. PubMed ID: 17885485
[TBL] [Abstract][Full Text] [Related]
12. 3p21, 5q21, and 9p21 allelic deletions are frequently found in normal bronchial cells adjacent to non-small-cell lung cancer, while they are unusual in patients with no evidence of malignancy.
Sanz-Ortega J; Saez MC; Sierra E; Torres A; Balibrea JL; Hernando F; Sanz-Esponera J; Merino MJ
J Pathol; 2001 Nov; 195(4):429-34. PubMed ID: 11745674
[TBL] [Abstract][Full Text] [Related]
13. Frequent loss of heterozygosity on chromosomes 7 and 9 in benign epithelial ovarian tumours.
Roy WJ; Watson RH; Hitchcock A; Campbell IG
Oncogene; 1997 Oct; 15(17):2031-5. PubMed ID: 9366520
[TBL] [Abstract][Full Text] [Related]
14. p53 mutation, allele loss on chromosome 17p, and DNA content in ovarian carcinoma.
McManus DT; Murphy M; Arthur K; Hamilton PW; Russell SE; Toner PG
J Pathol; 1996 Jun; 179(2):177-82. PubMed ID: 8758210
[TBL] [Abstract][Full Text] [Related]
15. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors.
Wada H; Enomoto T; Fujita M; Yoshino K; Nakashima R; Kurachi H; Haba T; Wakasa K; Shroyer KR; Tsujimoto M; Hongyo T; Nomura T; Murata Y
Cancer Res; 1997 Dec; 57(23):5379-85. PubMed ID: 9393763
[TBL] [Abstract][Full Text] [Related]
16. Primary peritoneal malignant mixed Müllerian tumors. A clinicopathologic, immunohistochemical, and genetic study.
Shen DH; Khoo US; Xue WC; Ngan HY; Wang JL; Liu VW; Chan YK; Cheung AN
Cancer; 2001 Mar; 91(5):1052-60. PubMed ID: 11251959
[TBL] [Abstract][Full Text] [Related]
17. Clonal divergence and genetic heterogeneity in clear cell renal cell carcinomas with sarcomatoid transformation.
Jones TD; Eble JN; Wang M; Maclennan GT; Jain S; Cheng L
Cancer; 2005 Sep; 104(6):1195-203. PubMed ID: 16047350
[TBL] [Abstract][Full Text] [Related]
18. p53 mutation is infrequent in clear cell carcinoma of the ovary.
Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
[TBL] [Abstract][Full Text] [Related]
19. Allele loss on chromosome arm 6q and fine mapping of the region at 6q27 in epithelial ovarian cancer.
Cooke IE; Shelling AN; Le Meuth VG; Charnock ML; Ganesan TS
Genes Chromosomes Cancer; 1996 Apr; 15(4):223-33. PubMed ID: 8703848
[TBL] [Abstract][Full Text] [Related]
20. Ascitic fluid cytology of a malignant mixed Müllerian tumor of the peritoneum: a report of two cases with special reference to p53 status.
Kato N; Motoyama T
Diagn Cytopathol; 2009 Apr; 37(4):281-5. PubMed ID: 19217035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
